Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010–2019

• DOI: 10.1111/jne.13473
• Publication Date: 2024-11-28T06:36:44Z
• Authors: Marlies Maly; Eduard Callebout; Suzane Ribeiro; Anne Hoorens; Saskia Carton; Pieter‐Jan Cuyle; Timon Vandamme; Ivan Borbath; Pieter Demetter; Nancy Van Damme; Liesbet Van Eycken; Chris Verslype; Karen Geboes
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Human medicine

Abstract The prevalence of gastric NEN is estimated worldwide at 8.9% all gastroenteropancreatic neuroendocrine neoplasm (GEP‐NEN) and only 0.3%–1% neoplasms, but rising in the last decades. aim this project was to map epidemiology (gNEN) Belgium. This a population‐wide retrospective cohort study over 10 years (2010–2019), based on data from Belgian Cancer Registry. A total 641 patients were included; 605 with gNEN 36 MiNEN. AAIR 0.67 per 100,000 person‐years, increasing slight female predominance (55.4%). Neuroendocrine carcinoma (NEC) accounted for 15.7% ( N = 95), an 0.11 person‐years. other 510 diagnosed gNET: G1 NET most prevalent (54.3%) followed by G2 (32.5%) G3 (3.5%). Concerning clinical classification (type) gNET, diagnosis type 1 tumors presumed 67.6%, 3 17.1% 2 0.6% patients. In 3.8% patients, explicitly stated pathology report. Stage IV 13.4% 81). favorable evolution reporting seen. Some variables—for example, gNET—were heavily underreported, stressing importance registries integrating pathological information.